Clinical or echocardiographic mid-term responses to cardiac resynchronization therapy (CRT) may have a different influence on long-term prognosis of heart failure patients treated with CRT. The aim of the study was to establish which definition of response to CRT, clinical or echocardiographic, best predicts long-term prognosis.
introduction
The long-term survival benefits of cardiac resynchronization therapy (CRT) demonstrated in various trials have changed the clinical management of heart failure patients. [1] [2] [3] CRT improves left ventricular (LV) performance by partially restoring more physiological and synchronous contraction. As a consequence, significant improvements in clinical status and reduction in LV volumes and mitral regurgitation have been reported. Ultimately, these favorable changes result in improved long-term morbidity and mortality rates. 4, 5 Most of the landmark trials have evaluated the efficacy of CRT by means of improvement in clinical status and/or a reduction of LV end-systolic volume (LVESV) at mid-term follow-up. 6, 7 The value of these surrogate end points relies on their ability to predict long-term survival. 8, 9 Thus far, only few studies have attempted to evaluate the long-term survival implications of mid-term clinical and echocardiographic responses to CRT (commonly assessed at 3-6 months follow-up). 4, 5, 10 In a series of 141 heart failure patients treated with CRT, mid-term LV reverse remodeling had superior accuracy to predict long-term survival than improvement in clinical parameters. 5 A recent subanalysis of the CARE-HF trial showed that LV volumes measured 3 months after CRT implantation predicted long-term survival on univariable analysis with a hazard ratio higher than LV volumes at baseline; however, LV volumes (baseline and after 3 months) were not independent determinants of long-term survival. 10 In view of these results, it remains unclear whether clinical or echocardiographic mid-term responses to CRT have an influence on long-term prognosis of heart failure patients treated with CRT. Accordingly, the present study aimed to establish which definition of CRT response at mid-term follow-up (clinical improvement or LV reverse remodeling) best predicts long-term prognosis.
MetHods

Patient population and protocol
A total of 679 heart failure patients undergoing CRT implantation were included. According to current guidelines, the inclusion criteria were: New York Heart Association (NYHA) functional class III-IV, sinus rhythm, LV ejection fraction ≤35%, and QRS duration ≥120 ms. Etiology of heart failure was considered ischemic in the presence of significant coronary artery disease (>50% stenosis in ≥1 major epicardial coronary artery) on coronary angiography and/or a history of myocardial infarction or revascularization.
All patients underwent a complete history and physical examination, 12-lead surface ECG and transthoracic echocardiogram prior to CRT implantation and at 6 months follow-up. Clinical and ECG variables recorded included NYHA functional class, medication, hemoglobin level, renal dysfunction (estimated glomerular filtration rate ≤60 ml/min/1.73m2), 11, 12 and QRS duration.
In addition, the number of hospitalizations for heart failure within 6 months follow-up was recorded. All clinical data were prospectively entered into the departmental Cardiology Information System (EPD-Vision ® , Leiden University Medical Center, Leiden, the Netherlands) and retrospectively analyzed.
The echocardiographic examination consisted of comprehensive evaluation of LV volumes and function, and severity of mitral regurgitation, if present.
Finally, the clinical and echocardiographic responses to CRT were defined based on clinical improvement and LV reverse remodeling at 6 months follow-up, respectively, as previously described. 6 All patients were prospectively followed-up for the occurrence of death. To test whether the clinical and echocardiographic mid-term responses to CRT could independently predict mortality, the long-term follow-up started at 6 months after CRT implantation.
echocardiography
Transthoracic echocardiography was performed with the patients in the left lateral decubitus position using a commercially available ultrasound transducer and equipment (M4S probe, Vivid 7, GE-Vingmed, Horten, Norway). All transthoracic echocardiographic examinations were performed prior to CRT implantation and at 6 months follow-up. All images were digitally stored on hard disks for offline analysis (EchoPAC version 7.0.0 and 108.1.5 GE-Vingmed, Horten, Norway).
A complete 2-dimensional and color Doppler echocardiographic examination was performed. LV end-diastolic (LVEDV) and LVESV were calculated using Simpson's biplane method of discs. LV ejection fraction was calculated and expressed as a percentage. 13 Intra-and inter-observer variability for the assessment of LV volumes and LVEF were previously reported. 14 Severity of mitral regurgitation was graded semi-quantitatively from color-flow Doppler data using the 4-chamber apical views according to the ACC/AHA guidelines. Mitral regurgitation was classified as mild (jet area/left atrial area <20%), moderate (jet area/left atrial area 20-40%) and severe (jet area/left atrial area >40%). 15 
crt implantation
All patients received a biventricular pacemaker with cardioverter-defibrillator function (Contak Renewal 4RF, Boston Scientific St. Paul, Minnesota; or InSync Sentry, Medtronic Inc. Minneapolis, Minnesota; Lumax 340 HF-T, Biotronik, Berlin). The right atrial and ventricular leads were positioned conventionally. All LV leads were implanted transvenously, and positioned preferably in a (postero-)lateral vein. A coronary sinus venogram was obtained using a balloon catheter, followed by the insertion of the LV pacing lead. An 8-F guiding catheter was used to place the LV lead (Easytrak, Boston Scientific, or Attain-SD, Medtronic, or Corox OTW Biotronik) in the coronary sinus.
definition of crt response
As previously reported, clinical response to CRT was defined as improvement ≥1 in NYHA functional class at 6 months follow-up and echocardiographic response to CRT was defined by the occurrence of LV reverse remodeling (reduction ≥15% in LVESV at 6 months follow-up). 6 All clinical and echocardiographic analyses were performed by independent blinded physicians.
study end points
All patients were followed-up regularly (every 3-6 monthly intervals) and all deaths occurring after 6 months follow-up were recorded as events. All-cause mortality was adjudicated by physicians blinded to the clinical and echocardiographic data.
statistical analysis
All continuous variables are presented as mean and standard deviation. Categorical variables are presented as frequencies and percentages, and were compared using Chi-square test. Student T test was used to compare unpaired continuous variables. First, the cumulative event rates 6 months after CRT implantation were calculated using the Kaplan-Meier method and dichotomizing the population according to the clinical and echocardiographic response to CRT. The log-rank tests for time-to-event data with respect to all-cause mortality were used for statistical comparison between 2 patient groups. In order to identify independent predictors of all-cause mortality, mul-tivariable Cox proportional-hazards models were constructed with backward selection (Correct) model. All significant univariable clinical and echocardiographic predictors at baseline, clinical and echocardiographic response to CRT at 6 months follow-up, and hospitalizations for heart failure within 6 months follow-up were entered in the multivariable model as covariates. The Cox proportional-hazards models were then used to estimate hazard ratios and 95% confidence intervals (CI) for those independent variables. To avoid multicollinearity between the univariable predictors, a correlation coefficient of <0.7 (corresponding to a tolerance level of >0.5) was set. Second, the cumulative event rates 6 months after CRT implantation were calculated using the Kaplan-Meier method after dividing the populations in 4 different subgroups based on combined clinical and/or echocardiographic response: patients with both clinical and echocardiographic response, patients with clinical but not echocardiographic response, patients with echocardiographic but not clinical response and patients with neither clinical or echocardiographic response. The log-rank tests for time-to-event data with respect to all-cause mortality were used for statistical comparison between 4 patient subgroups All statistical tests were 2-sided, and a p value <0.05 was considered significant. A statistical software program SPSS 16.0 (SPSS Inc, Chicago, IL, USA) was used for all statistical analyses.
resuLts overall patient population
Of the 679 patients enrolled in the study, 16 (2.4%) patients died before 6 months follow-up and these patients were excluded from further analysis. Therefore, the patient population consisted of 663 heart failure patients.
Baseline clinical, ECG and echocardiographic characteristics are reported in Table 1 . The mean age was 65±11 years and 79% of the patients were male. All patients had dilated with depressed LV systolic function.
At 6 months follow-up, 510 (77%) patients showed an improvement ≥1 in NYHA functional class (clinical response to CRT) and 412 (62%) patients showed ≥15% reduction of LVESV (echocardiographic response to CRT). Furthermore, the patient population (n = 663) was divided in 4 subgroups based on combined clinical and/or echocardiographic response to CRT at 6 months follow-up: 348 (52.4%) patients showed both clinical and echocardiographic response, 159 (24%) patients showed clinical but not echocardiographic response, 64 (9.7%) were echocardiographic but not clinical responders, and 92 (13.9%) patients did not show either clinical or echocardiographic response. 
survivors versus non-survivors
During a mean follow-up of 37±22 months, 140 (21%) patients died. Baseline parameters of the survivors versus the non-survivors are reported in Table 2 . Of note, the survivors were younger, had less frequently diabetes, ischemic etiology of heart failure, and NYHA functional class IV. Interestingly, the survivors had higher hemoglobin levels and also more preserved renal function. Regarding the echocardiographic data at baseline, the survivors had smaller LVESV, higher LV ejection fraction and less frequently severe mitral regurgitation. There were 7 (1.3%) hospitalizations for heart failure in the survivors and 8 (5.7%) in the non-survivors (p = 0.002) within 6 months follow-up. The survivors were more frequently clinical responders as compared to the nonsurvivors (78% versus 70%, p = 0.037). Moreover, the survivors showed higher echocardiographic response rate as compared to the non-survivors (69% versus 37%, p <0.001). The clinical (change in NYHA functional class at 6 months followup) and the echocardiographic (change in LVEDV, LVESV and LV ejection fraction) improvements are illustrated in Figure 1 .
clinical and echocardiographic response to crt versus long-term mortality
Clinical and echocardiographic responses to CRT were both significantly related to all-cause mortality. When the patient population was dichotomized based on clinical response to CRT, a cumulative 2%, 7% and 12% of the patients with improvement in ≥1 NYHA functional class died by 12, 24 and 36 months follow-up, respectively. In contrast, a respective 7%, 18% and 23% of the patients without improvement in ≥1 NYHA functional class died during the same time period (log-rank p = 0.004: Figure 2A ). When the patient population was dichotomized based on echocardiographic response to CRT, a cumulative 1%, 4% and 8% of the patients with LV reverse remodeling died by 12, 24 and 36 months follow-up, respectively. In contrast, a respective 8%, 19% and 27% of the patients without LV reverse remodeling died during the same time period (log-rank p <0.001) ( Figure 2B ).
To identify whether clinical and echocardiographic responses were independent predictors of all-cause mortality during follow-up, significant univariable predictors with a p value <0.05 were entered into the Cox proportional-hazard model as covariates. On multivariable analysis, echocardiographic response (hazard ratio, 0.35; 95% CI, 0.25-0.50; p <0.001) but not clinical response was independently associated with a superior survival.
As expected, the main cause of death was cardiovascular (91[65%] of 140 patients) and specifically related to progression of heart failure (81[89%] of 91 patients). Interestingly, echocardiographic non-responder patients died more frequently for cardiovascular reasons as compared to responder patients (65 [74%] vs. 26[50%] patients, p= 0.004).
Finally, dividing the patient population in 4 subgroups based on combined clinical and/or echocardiographic response, patients with both clinical and echocardiographic response to CRT and patients with echocardiographic but not clinical response had significantly lower mortality (12.9% and 10.9%, respectively) as compared to patients with clinical but not echocardiographic response or patients without any response to CRT (nor clinical or echocardiographic), in whom mortality rates were 32.7% and 39.1%, respectively (chi-square = 48.72, p <0.001). Figure 3 represents the Kaplan-Meier survival curves of these 4 subgroups of patients showing superior survival for patients with both clinical and echocardiographic response to CRT and for patients with echocardiographic but not clinical response to CRT. 
discussion
The present study demonstrated that reduction of ≥15% LVESV, regardless changes in clinical status, was a predictor of all-cause mortality in heart failure patients treated with CRT. Specifically, LV reverse remodeling was an important and independent predictor of outcome in CRT recipients over other well established predictors of mortality in the general heart failure population.
clinical and echocardiographic response to crt
Along the various single-and multi-center trials on CRT, definition of response to CRT has widely varied. 16 Different clinical and echocardiographic parameters have been used to evaluate the efficacy of CRT. In addition, the response to CRT has been evaluated at different time points, most commonly at 3 or 6 months follow-up. However, it has been repeatedly shown that clinical and echocardiographic CRT response may not coincide and, indeed, a significant percentage of patients who showed an improvement in clinical end points did not show any improvement in echocardiographic parameters (≥15% LV reverse remodeling or significant improvement in LV ejection fraction). 6, 16, 17 In the present study, 77% of the patients showed an improvement in NYHA function class of at least 1-point whereas 62% showed ≥15% reduction in LVESV. This confirms previous findings and suggests the presence of a placebo effect that may overestimate the benefits of CRT when the response is defined according to clinical criteria. However, it may be more interesting to evaluate whether this improvement in clinical status or in echocardiographic parameters at mid-term follow-up conveys or not a superior long-term survival. Indeed, the appropriateness of surrogate end points, such as NYHA functional class or LV reverse remodeling, to evaluate the efficacy of heart failure therapies depends on the strength of the statistical relationship between the change in the surrogate end points over time and the clinical outcome. 8
response to crt versus long-term survival
The present study demonstrated that the occurrence of significant LV reverse remodeling at 6 months follow-up was related with superior long-term survival. In contrast, improvement in NYHA functional class was not associated with improved long-term survival. This was also confirmed dividing the patient population in 4 subgroups based on combined clinical and/or echocardiographic response CRT response. The patients with echocardiographic response to CRT (clinical and echocardiographic or only echocardiographic CRT response) had better survival as compared to the patients without echocardiographic response to CRT (Figure 3 ). Previously, Yu et al. 5 have shown in 141 heart failure patients that LVESV reduction was independently associated to mid-term outcome after CRT. The authors found a relationship between reduction of LVESV and mid-term clinical outcome. However, the association between improvement in clinical status (defined by ≥1 point in NYHA functional class) and all-cause and cardiovascular mortality was not evaluated. More recently, the results of the REVERSE, MADIT-CRT and RAFT trials have shown that in mildly symptomatic heart failure patients (NYHA functional class I-II), CRT reduced the number of heart failure re-hospitalizations, induced a significant LV reverse remodeling and improved the long-term survival. [18] [19] [20] This improvement in long-term survival might be related to improvement in LV performance and LV reverse remodeling rather than improvements in NYHA functional class since the included patients were asymptomatic or mildly symptomatic. The present study confirms and extends these preliminary results in over 650 heart failure patients treated with CRT. LV reverse remodeling was independently related to all cause mortality (hazard ratio, 0.34; 95% CI, 0.25-0.50; p <0.001) together with age, presence of diabetes, renal dysfunction, and heart failure hospitalizations. These clinical parameters (age, diabetes, systolic blood pressure, renal dysfunction, and heart failure hospitalizations,) are well known strong prognosticators in patients with advanced heart failure. [21] [22] [23] However, thus far, the effects of CRT on LV dimensions and its implications on long-term survival have not been evaluated together with these clinical variables. 4, 5 The fact that LV reverse remodeling at mid-term follow-up was still an independent predictor of long-term outcome after adjusting for these powerful risk factors underlines the relevance of the assessment of CRT response at mid-term follow-up based on LV reverse remodeling.
study limitations
The study was retrospective and reported the experience of a single center. Data on LV lead position was not included in the present study. The influence of this parameter on CRT response and outcome has been well -described in observational and randomized trials. However, the impact of LV lead position on CRT response and outcome was beyond the scope of the present study which focused on the prognostic implications of clinical and/or echocardiographic response. The percentage of betablocker use was relatively low but still higher as compared to previous randomized trials (MIRACLE and COMPANION) and similar to the CARE-HF trial but lower than the recent REVERSE, MADIT-CRT and RAFT trials. 1, 3, [18] [19] [20] 24 However all the patients received the maximum tolerated dose of beta-blocker.
concLusions
In a large population of heart failure patients treated with CRT, the reduction of LVESV at mid-term follow-up demonstrated to be a better predictor of long-term survival than improvement in clinical status. In addition, LV reverse remodeling was an important and independent predictor of outcome in these patients together with other well established predictors of long-term survival.
